Explore the vast range of titles available.

ZF2001 contains a tandem-repeat dimeric receptor-binding domain of the SARS-CoV-2 spike protein with aluminum hydroxide adjuvant. In a phase 3 trial, 28,904 participants in five countries were randomly assigned to receive three doses of ZF2001 or placebo. After 6 months of follow-up, efficacy was 76% against infection, 87% against critical or severe disease, and 86% against death. Most side effects were local, low-grade, and transient.

\"This is a close study of Gao Village twenty years after the author, an anthropologist and native of Gao Village, wrote his original ethnography Gao Village. It combines ethnographic analysis, personal vignettes, and a number of fascinating stories, which presents a convincing yet complex picture of how Gao villagers interact with the outside world. With his sympathetic and insider's approach, the author argues that rural Chinese display great entrepreneurship and inner strength of self-improvement; they are active contributors to China's economic boom\"-- Provided by publisher.

Heterologous boost vaccination has been proposed as an option to elicit stronger and broader, or longer-lasting immunity. We assessed the safety and immunogenicity of heterologous immunization with a recombinant adenovirus type-5-vectored Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein-subunit-based COVID-19 vaccine (ZF2001, hereafter referred to as ZF). We conducted a randomized, observer-blinded, placebo-controlled trial, in which healthy adults aged 18 years or older, who have received 1 dose of Convidecia, with no history of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, were recruited in Jiangsu, China. Sixty participants were randomly assigned (2:1) to receive either 1 dose of ZF2001 or placebo control (trivalent inactivated influenza vaccine (TIV)) administered at 28 days after priming, and received the third injection with ZF2001 at 5 months, referred to as CV/ZF/ZF (D0-D28-M5) and CV/ZF (D0-M5) regimen, respectively. Sixty participants were randomly assigned (2:1) to receive either 1 dose of ZF2001 or TIV administered at 56 days after priming, and received the third injection with ZF2001 at 6 months, referred to as CV/ZF/ZF (D0-D56-M6) and CV/ZF (D0-M6) regimen, respectively. Participants and investigators were masked to the vaccine received but not to the boosting interval. Primary endpoints were the geometric mean titer (GMT) of neutralizing antibodies against wild-type SARS-CoV-2 and 7-day solicited adverse reactions. The primary analysis was done in the intention-to-treat population. Between April 7, 2021 and May 6, 2021, 120 eligible participants were randomly assigned to receive ZF2001/ZF2001 (n = 40) or TIV/ZF2001 (n = 20) 28 days and 5 months post priming, and receive ZF2001/ZF2001 (n = 40) or TIV/ZF2001 (n = 20) 56 days and 6 months post priming. Of them, 7 participants did not receive the third injection with ZF2001. A total of 26 participants (21.7%) reported solicited adverse reactions within 7 days post boost vaccinations, and all the reported adverse reactions were mild, with 13 (32.5%) in CV/ZF/ZF (D0-D28-M5) regimen, 7 (35.0%) in CV/ZF (D0- M5) regimen, 4 (10.0%) in CV/ZF/ZF (D0-D56-M6) regimen, and 2 (10.0%) in CV/ZF (D0-M6) regimen, respectively. At 14 days post first boost, GMTs of neutralizing antibodies in recipients receiving ZF2001 at 28 days and 56 days post priming were 18.7 (95% CI 13.7 to 25.5) and 25.9 (17.0 to 39.3), respectively, with geometric mean ratios of 2.0 (1.2 to 3.5) and 3.4 (1.8 to 6.4) compared to TIV. GMTs at 14 days after second boost of neutralizing antibodies increased to 107.2 (73.7 to 155.8) in CV/ZF/ZF (D0-D28-M5) regimen and 141.2 (83.4 to 238.8) in CV/ZF/ZF (D0-D56-M6) regimen. Two-dose schedules of CV/ZF (D0-M5) and CV/ZF (D0-M6) induced antibody levels comparable with that elicited by 3-dose schedules, with GMTs of 90.5 (45.6, 179.8) and 94.1 (44.0, 200.9), respectively. Study limitations include the absence of vaccine effectiveness in a real-world setting and current lack of immune persistence data. Heterologous boosting with ZF2001 following primary vaccination with Convidecia is more immunogenic than a single dose of Convidecia and is not associated with safety concerns. These results support flexibility in cooperating viral vectored and recombinant protein vaccines. Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine; ClinicalTrial.gov NCT04833101.

The mobility of dislocation loops in materials is a principle factor in understanding the mechanical strength, and the evolution of microstructures due to deformation and radiation. In body-centered cubic (BCC) iron, the common belief is that interstitial dislocation loops are immobile once formed. However, using self-adaptive accelerated molecular dynamics (SSAMD), a new diffusion mechanism has been discovered for interstitial dislocation loops. The key aspect of the mechanism is the changing of the habit planes between the {100} plane and the {110} plane, which provides a path for the loops to diffuse one-dimensionally. The migration behavior modeled with SSAMD is further confirmed by in-situ transmission electron microscopy (TEM) measurements, and represents a significant step for understanding the formation of loop walls and the mechanical behavior of BCC Fe under irradiation. The mobility of dislocation loops in materials is of key importance to understanding their deformation behavior. Here the authors using self-adaptive accelerated molecular dynamics show self-diffusion of interstitial loops in body-centered cubic (BCC) iron by changing its habit plane as also confirmed by transmission electron microscopy (TEM) measurements.

Following a proposal made by the French and German Ministers for Foreign Affairs at the November 2020 Paris Peace Forum, 4 global partners, the Food and Agriculture Organization (FAO), the World Organization for Animal Health (OIE), the United Nations Environment Programme (UNEP), and the World Health Organization (WHO), in May 2021 established the interdisciplinary One Health High-Level Expert Panel (OHHLEP) (https://www.who.int/groups/one-health-high-level-expert-panel) to enhance their cross-sectoral collaboration. There is no shortage of “One Health” definitions in the published literature and among institutions and organizations. [...]an immediate priority for OHHLEP was to develop consensus around a working definition as a solid basis to support a common understanding among the panel members and the partner organizations. Key underlying principles including 1. equity between sectors and disciplines; 2. sociopolitical and multicultural parity (the doctrine that all people are equal and deserve equal rights and opportunities) and inclusion and engagement of communities and marginalized voices; 3. socioecological equilibrium that seeks a harmonious balance between human–animal–environment interaction and acknowledging the importance of biodiversity, access to sufficient natural space and resources, and the intrinsic value of all living things within the ecosystem; 4. stewardship and the responsibility of humans to change behavior and adopt sustainable solutions that recognize the importance of animal welfare and the integrity of the whole ecosystem, thus securing the well-being of current and future generations; and 5. transdisciplinarity and multisectoral collaboration, which includes all relevant disciplines, both modern and traditional forms of knowledge and a broad representative array of perspectives. PLoS Pathog 18(6): e1010537. https://doi.org/10.1371/journal.ppat.1010537 About the Authors: One Health High-Level Expert Panel (OHHLEP) Wiku B. Adisasmito Affiliation: Universitas Indonesia, Depok, West Java, Indonesia Salama Almuhairi Affiliation: National Emergency Crisis and Disasters Management Authority, Abu Dhabi, United Arab Emirates Casey Barton Behravesh Affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America Pépé Bilivogui Affiliation: World Health Organization, Guinea Country Office, Conakry, Guinea Salome A. Bukachi Affiliation: Institute of Anthropology, Gender and African Studies, University of Nairobi, Nairobi, Kenya Natalia Casas Affiliation: National Ministry of Health, Autonomous City of Buenos Aires, Argentina Natalia Cediel Becerra Affiliation: School of Agricultural Sciences, Universidad de La Salle, Bogotá, Colombia Dominique F. Charron Affiliation: International Development Research Centre, Ottawa, Canada Abhishek Chaudhary Affiliation: Indian Institute of Technology (IIT), Kanpur, India Janice R. Ciacci Zanella Affiliation: Brazilian Agricultural Research Corporation (Embrapa), Embrapa Swine and Poultry, Concórdia, Santa Catarina, Brazil Andrew A. Cunningham Affiliation: Institute of Zoology, Zoological Society of London, London, United Kingdom Osman Dar Affiliations Global Operations Division, United Kingdom Health Security Agency, London, United Kingdom, Global Health Programme, Chatham House, Royal Institute of International Affairs, London, United Kingdom Nitish Debnath Affiliation: Fleming Fund Country Grant to Bangladesh, DAI Global, Dhaka, Bangladesh Baptiste Dungu Affiliations Afrivet B M, Pretoria, South Africa, Faculty of Veterinary Science, University of Kinshasa, Kinshasa, Democratic Republic Congo Elmoubasher Farag Affiliation: Ministry of Public Health, Health Protection & Communicable Diseases Division, Doha, Qatar George F. Gao Affiliation: Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of China David T. S. Hayman Affiliation: Molecular Epidemiology and Public Health Laboratory, Massey University, Palmerston North, New Zealand Margaret Khaitsa Affiliation: Mississippi State University, Starkville, Mississippi,

Beginning with results for the leading-twist two-particle distribution amplitudes of π - and K -mesons, each of which exhibits dilation driven by the mechanism responsible for the emergence of hadronic mass, we develop parameter-free predictions for the pointwise behaviour of all π and K distribution functions (DFs), including glue and sea. The large- x behaviour of each DF meets expectations based on quantum chromodynamics; the valence-quark distributions match extractions from available data, including the pion case when threshold resummation effects are included; and at ζ 5 = 5.2 GeV, the scale of existing measurements, the light-front momentum of these hadrons is shared as follows: ⟨ x valence ⟩ π = 0.41 ( 4 ) , ⟨ x glue ⟩ π = 0.45 ( 2 ) , ⟨ x sea ⟩ π = 0.14 ( 2 ) ; and ⟨ x valence ⟩ K = 0.42 ( 3 ) , ⟨ x glue ⟩ K = 0.44 ( 2 ) , ⟨ x sea ⟩ K = 0.14 ( 2 ) . The kaon’s glue and sea distributions are similar to those in the pion, although the inclusion of mass-dependent splitting functions introduces some differences on the valence-quark domain. This study should stimulate improved analyses of existing data and motivate new experiments sensitive to all π and K DFs. With little known empirically about the structure of the Standard Model’s (pseudo-) Nambu-Goldstone modes and analyses of existing, limited data being controversial, it is likely that new generation experiments at upgraded and anticipated facilities will provide the information needed to resolve the puzzles and complete the picture of these complex bound states.

Monoclonal antibodies （mAbs） blocking immune checkpoint molecules, especially programmed cell death l （PD-1） and its ligands programmed cell death 1 ligand 1 （PD-L1） and ligand 2 （PD-L2）, are currently been in- vestigated for treatment of various tumors [1-3]. PD-L1 and PD-L2 are usually upregulated on the surface of mul- tiple tumor cells to mediate immune tolerance through the interaction with inhibitory PD-1 molecule [4].

COVID-19 vaccines have been successful, but their duration and level of protection could be improved to cover all SARS-CoV-2 variants. A self-assembling enveloped virus-like particle vaccine combining features of mRNA and protein vaccines might provide a way forward.